{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T19:11:13Z","timestamp":1774293073895,"version":"3.50.1"},"reference-count":20,"publisher":"Tech Science Press","issue":"6","license":[{"start":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T00:00:00Z","timestamp":1716422400000},"content-version":"vor","delay-in-days":143,"URL":"https:\/\/doi.org\/10.32604\/TSP-CROSSMARKPOLICY"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OR"],"published-print":{"date-parts":[[2024]]},"DOI":"10.32604\/or.2024.046885","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T06:43:09Z","timestamp":1714027389000},"page":"1031-1036","update-policy":"https:\/\/doi.org\/10.32604\/tsp-crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma: a single-institution experience"],"prefix":"10.32604","volume":"32","author":[{"given":"CONSTANTINE N.","family":"LOGOTHETIS","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"NATHAN P.","family":"HORVAT","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TONY","family":"KURIAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CELESTE","family":"BELLO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JULIO","family":"CHAVEZ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LEIDY","family":"ISENALUMHE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"BIJAL","family":"SHAH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LUBOMIR","family":"SOKOL","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HAYDER","family":"SAEED","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JAVIER","family":"PINILLA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SAMEH","family":"GABALLA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"17807","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pathol.2019.08.012","article-title":"Marginal zone B-cell lymphoma: Lessons from Western and Eastern diagnostic approaches","volume":"52","author":"Nakamura","year":"2020","journal-title":"Pathology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/aol-20-28","article-title":"Epidemiology of marginal zone lymphoma","volume":"5","author":"Cerhan","year":"2021","journal-title":"Annals of Lymphoma"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1080\/10428190701457949","article-title":"Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma","volume":"48","author":"Lossos","year":"2007","journal-title":"Leukemia & Lymphoma"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type","volume":"102","author":"Conconi","year":"2003","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","article-title":"Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: Eastern cooperative oncology group protocol E4402","volume":"32","author":"Kahl","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: The BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/bjh.15843","volume":"185","author":"Becnel","year":"2019","journal-title":"British Journal of Haematology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood-2016-06-720599","article-title":"A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma","volume":"129","author":"Kiesewetter","year":"2017","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40880-019-0403-7","article-title":"Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: Consortium for improving survival of lymphoma (CISL) study","volume":"39","author":"Oh","year":"2019","journal-title":"Cancer Communications"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/bjh.16264","article-title":"First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the polish lymphoma research group PLRG4","volume":"188","author":"Walewski","year":"2020","journal-title":"British Journal of Haematology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-hodgkin\u2019s lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","article-title":"Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: Improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy","volume":"35","author":"Zucca","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"650","DOI":"10.6004\/jnccn.2019.0029","article-title":"NCCN guidelines insights: B-cell lymphomas, version 3.2019","volume":"17","author":"Zelenetz","year":"2019","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e104-11","DOI":"10.1016\/S2352-3026(14)00021-0","article-title":"First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): A multicentre, single-arm, phase 2 trial","volume":"1","author":"Salar","year":"2014","journal-title":"Lancet Haematology"},{"key":"ref15","first-page":"368","article-title":"Staging non-hodgkin lymphoma","volume":"55","author":"Armitage","year":"2005","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"Journal of Clinical Oncology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hon.2773","article-title":"Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: Experience on 65 patients","volume":"38","author":"Morigi","year":"2020","journal-title":"Journal of Hematology & Oncology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1182\/bloodadvances.2021006844","article-title":"An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma","volume":"6","author":"Alderuccio","year":"2022","journal-title":"Blood Advances"}],"container-title":["Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.techscience.com\/files\/or\/2024\/TSP_OR-32-6\/OncolRes-32-06-46885\/OncolRes-32-46885.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T09:20:22Z","timestamp":1741252822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v32n6\/56595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024]]},"published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.32604\/or.2024.046885","relation":{},"ISSN":["1555-3906"],"issn-type":[{"value":"1555-3906","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"2023-10-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-23","order":2,"name":"published","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}]}}